Kaleido gains permanent German HMV listing for its system
The listing, effective 5 November 2026, covers the DBLG2 algorithm with Dexcom G7 and can reduce the need for individual justification by statutory health insurers.
See the latest news and media coverage for Kaleido. We track all announcements, press releases, and industry mentions in real time, all in one place.
Insulin pump brand and diabetes technology provider
hellokaleido.comLast updated
In short: Kaleido gained a permanent German HMV listing for its DBLG2 system with Dexcom G7.
The listing, effective 5 November 2026, covers the DBLG2 algorithm with Dexcom G7 and can reduce the need for individual justification by statutory health insurers.
The EASD 2026 data show strong Time in Range, best-in-class hypoglycaemia outcomes and lowest glycaemic variability. A second webinar with Dr Stephan Arndt follows on 27 October.
Data from nearly 4,000 adults with type 1 diabetes show best-in-class hypoglycaemia results and lowest glycaemic variability, presented in a German-language webinar for healthcare professionals.
Across 3,918 adults with type 1 diabetes, median time in range was 72.2% and time below 54 mg/dL was 0.21%.
The Kaleido insulin patch pump worn on the arm. [Image courtesy of ViCentra] ViCentra announced today that it made its Kaleido automated insulin pump immediately...
ViCentra, a European medical technology company focused on transforming insulin delivery for people living with diabetes, has announced the close of an $85 million Series...
Led by new investor Innovation Industries, with matching contributions from existing investors, Partners in Equity and Invest-NL, the $85M round also drew support from EQT...
The company from Utrecht hopes to introduce its remarkably small pump for diabetes patients on the US market.
Track Kaleido and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kaleido and other trending companies.